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Abstract Plasmodium vivax relapse infections occur following activation of latent liver-stages 
parasites (hypnozoites) causing new blood-stage infections weeks to months after the initial 
infection. We develop a within-host mathematical model of liver-stage hypnozoites, and validate  
it against data from tropical strains of P. vivax. The within-host model is embedded in a P. vivax 
transmission model to demonstrate the build-up of the hypnozoite reservoir following new 
infections and its depletion through hypnozoite activation and death. The hypnozoite reservoir  
is predicted to be over-dispersed with many individuals having few or no hypnozoites, and some 
having intensely infected livers. Individuals with more hypnozoites are predicted to experience 
more relapses and contribute more to onwards P. vivax transmission. Incorporating hypnozoite 
killing drugs such as primaquine into first-line treatment regimens is predicted to cause substantial 
reductions in P. vivax transmission as individuals with the most hypnozoites are more likely to 
relapse and be targeted for treatment.
DOI: 10.7554/eLife.04692.001
Introduction
The study of the transmission dynamics of vector-borne diseases such as Plasmodium falciparum 
malaria has a rich history, with a theoretical foundation based on the Ross-Macdonald models (malERA 
Consultative Group on Modeling, 2011; Smith et al., 2012; Reiner et al., 2013; Smith et al., 2014), 
a class of mathematical models describing the transmission of a pathogen between human and 
vector hosts. In the case of P. falciparum, the parasite has a reservoir in both the human host and the 
Anopheles mosquito, with transmission occurring when a mosquito takes a blood meal from a human. 
Ross-Macdonald models have provided insights into the dynamics of P. falciparum transmission result-
ing in valuable guidance for historical and contemporary malaria control programmes, most notably 
the large reductions in transmission that are achievable if the lifespan of the mosquito is reduced 
through vector control (Macdonald, 1952a; Macdonald, 1952b).
In contrast to the extensive theory of the mathematical epidemiology of P. falciparum malaria 
(Smith et al., 2012), P. vivax malaria has been comparatively neglected. This is in spite of P. vivax being 
the geographically most widely distributed species of malaria in the world, causing in the region of 
80–300 million clinical episodes every year (Mueller et al., 2009a; Gething et al., 2012). P. falciparum 
*For correspondence: 
m.white08@imperial.ac.uk
Competing interests: See page 16
Funding: See page 16
Received: 10 September 2014
Accepted: 13 November 2014
Published: 18 November 2014
Reviewing editor: Mark Jit, 
London School of Hygiene  
& Tropical Medicine, and Public 
Health England, United Kingdom
 Copyright White et al. This 
article is distributed under the 
terms of the Creative Commons 
Attribution License, which 
permits unrestricted use and 
redistribution provided that the 
original author and source are 
credited.
RESEARCH ARTICLE
Epidemiology and global health
White et al. eLife 2014;3:e04692. DOI: 10.7554/eLife.04692 2 of 19
Research article
models are not applicable to P. vivax as they fail to account for the reservoir of dormant liver stages 
(hypnozoites) which give rise to relapsing infections—one of the defining characteristics of the biology 
and epidemiology of P. vivax (Mueller et al., 2009a). In natural transmission settings relapses are often 
undistinguishable from re-infections from new mosquito bites or recrudescences of existing blood-
stage infections. When the origin of renewed parasitemia following primary P. vivax infection is 
unknown, it can be classified as a recurrent infection (Battle et al., 2014).
Most existing models of malaria transmission do not account for the additional reservoir of para-
sites in the liver, but the hypnozoite reservoir has been incorporated into some P. vivax transmission 
models as a state to denote hypnozoite infection (Ishikawa et al., 2003; Chamchod and Beier, 2013; 
Roy et al., 2013) or as up to two broods of hypnozoites (Dezoysa et al., 1991). Relapse patterns and 
their implications for transmission have also been investigated using statistical distributions for the 
time to first relapse (Lover et al., 2014). Here we advance on existing work by considering how the 
number of hypnozoites in the liver contributes to patterns of relapse infections and the epidemiology 
and control of P. vivax.
When a P. vivax infected mosquito takes a blood meal from a human, sporozoites are injected into 
the skin and migrate to the liver, where they invade hepatocytes and develop into either actively 
dividing schizonts or dormant hypnozoites. The development of actively dividing schizonts may lead 
to a primary blood-stage infection and potentially clinical malaria (Mueller et al., 2013). Hypnozoites 
will lie dormant in the liver for weeks to years before activating to initiate new blood-stage infections. 
The biological mechanisms regulating the activation of hypnozoites remain unknown (Mueller et al., 
2009a), although a number of triggers for relapses have been proposed, including fever caused by 
other pathogens such as P. falciparum (Shanks and White, 2013) and exposure to Anopheles-specific 
proteins (Hulden and Hulden, 2011).
eLife digest Malaria is one of the world's most deadly infections, causing 100s of 1000s of 
deaths each year despite being both preventable and curable. Malaria is caused by Plasmodium 
parasites, which are transmitted between humans by mosquitoes. When a mosquito bites a human, 
Plasmodium is injected into the bloodstream with the mosquito's saliva. The parasite then travels 
through the bloodstream to the liver, infects liver cells and multiplies within those cells without 
causing any noticeable symptoms. After remaining silent in the liver for weeks or months, the now 
abundant parasite ruptures the host liver cell, re-enters the bloodstream, and begins infecting red 
blood cells. If another mosquito bites the infected individual and takes a blood meal, the parasite 
moves into the mosquito and the cycle of transmission continues.
There are several species of Plasmodium that are known to cause malaria. The most widely 
studied species is P. falciparum, which also causes one of the deadliest types of malaria. However, 
another Plasmodium species called P. vivax is the most widely distributed species and, despite 
being less virulent than P. falciparum, is particularly dangerous because it causes recurring malaria.
In contrast to P. falciparum, P. vivax has the ability to form hypnozoites: a dormant form of  
the parasite that can remain inside liver cells for long periods of time, sometimes for years. The 
reservoir of P. vivax hypnozoites can regularly populate the bloodstream with the infectious form of 
the parasite, triggering relapses of malaria. Even if an individual suffering a relapse receives prompt 
treatment to clear parasites in the blood, more parasites may emerge from the liver and cause new 
blood-stage infections.
White et al. developed a mathematical model to help understand how P. vivax is transmitted. 
Unlike many of the established models of malaria transmission, the new model accounts for the 
reservoir of P. vivax hypnozoites in the liver, and assumes that hypnozoites in the reservoir either 
die, or are activated and enter the bloodstream, at a constant rate. This produces patterns that 
closely match how often relapses occur in patients. White et al. go on to predict that although many 
infected people have few or no hypnozoites in their liver, some have many hypnozoites, and these 
people are more likely to suffer from malaria relapses. This suggests that if the initial treatments 
given to malaria sufferers incorporate additional drugs that kill the hypnozoites in the liver, then it 
may be possible to substantially reduce the extent of P. vivax transmission.
DOI: 10.7554/eLife.04692.002
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There is considerable geographical variation in the timing and frequency of P. vivax relapse infec-
tions, with strains from tropical areas having an average time to first relapse of 3–6 weeks and long-
latency strains from temperate areas relapsing within 6–9 months (Lover and Coker, 2013; Battle 
et al., 2014). Beyond the first relapse, periodic patterns in multiple relapses from a single mosquito 
bite have been observed (White, 2011). For example, following a single infection with a tropical 
strain of P. vivax the time until next relapse has been observed to increase with each successive 
relapse (Berliner et al., 1948; White, 2011). In contrast, temperate strains are associated with a 
long latency period until first relapse (of the order of 6 months) followed by short intervals between 
successive relapses (Coatney et al., 1950; Hankey et al., 1953; White, 2011). A descriptive epi-
demiology of P. vivax relapses will thus require estimation of three key quantities: (i) the time to 
first relapse, (ii) the number of relapses per primary infection, and (iii) the duration of hypnozoite 
carriage.
In this manuscript, a within-host model of hypnozoites in liver hepatocytes is developed to demon-
strate that many of the epidemiological patterns of relapse infections can be explained by making the 
assumption that hypnozoites activate and die at a constant rate. This model is integrated into the 
existing theory of Ross-Macdonald models to account for the relapse infections characteristic of 
P. vivax malaria. We use this model to provide qualitative insights into the relative contribution of 
relapses to P. vivax transmission and illustrate the consequences for controlling P. vivax with vector 
control and anti-malarial drugs.
Results
Within-host relapse model
Figure 1 shows the best fit within-host relapse model to data on time to first relapse infection 
from three ecological zones with tropical strains of P. vivax: South America, South East Asia and 
Melanesia (Battle et al., 2014). In each ecological zone, the number of hypnozoites N and the hyp-
nozoite activation rate α were correlated (see Figure 1—figure supplement 1). For example, a short 
time to relapse could be explained by a single fast activating hypnozoite or a large number of slow 
activating hypnozoites. Longitudinal data where multiple relapses are observed in individuals would 
allow better estimation of the number of hypnozoites in the liver and the duration of hypnozoite 
carriage.
The within-host model can be used to simulate beyond the first relapse infection. Figure 2 shows 
some sample relapse patterns from the within-host models for tropical and temperate strains of 
P. vivax. This model predicts notable dose-dependency with increased numbers of hypnozoites asso-
ciated with a greater number of relapses and shorter time to first relapse. Following the long latency 
to first relapse in temperate strains, the interval between subsequent relapses is considerably shorter. 
The within-host model assumes that hypnozoites act independently of each other, and hence the 
time to next relapsing hypnozoite is exponentially distributed. In particular we do not predict perio-
dicity between relapsing hypnozoites (in the absence of external triggers [White, 2011; Shanks 
and White, 2013]). If the simulated data are censored such that relapses occurring within 14 days of a 
previous relapse remain undetected (due to either prophylaxis by blood-stage anti-malarials or the 
presence of parasites from an existing infection) then there is an apparent periodicity in detected 
relapses. The observed periodicity of relapses will be determined by the duration of prophylactic 
protection and not via the biological mechanisms considered here. The periodicity in detected 
relapses is most evident for large numbers of hypnozoites with the period being determined by the 
assumed duration of prophylactic protection (Figure 2—figure supplement 1). However, as has been 
previously argued, periodicity in relapses could also be attributable to a cycle of fevers initiating hyp-
nozoite activation which in turn cause new blood-stage infections and malaria-associated fevers 
(White, 2011).
Figure 3 shows the predicted number of relapsing hypnozoites in a population exposed to P. vivax 
in the absence of new infections. For tropical strains the mean number of hypnozoites in the liver is 
expected to decrease exponentially, but the proportion of individuals carrying hypnozoites is expected 
to decrease at a slower rate as an individual can relapse even if they have just one hypnozoite (Figure 3A). 
For temperate strains the mean number of hypnozoites in the liver decreases slowly, as hypnozoites 
remain in the long-latency phase for approximately 6 months (Figure 3B). The model allows estima-
tion of time to second, third and consecutive relapses in addition to estimates of time to first relapse 
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Figure 1. Model parameterisation. Time to first relapse infection from the within-host model fitted to data from 
three ecological zones with tropical strains of P. vivax (Battle et al., 2014). The red curves show the model fits with 
estimated posterior median parameters.
DOI: 10.7554/eLife.04692.003
The following figure supplement is available for figure 1:
Figure supplement 1. MCMC chains and posterior distributions for Bayesian model fitting. 
DOI: 10.7554/eLife.04692.004
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Figure 2. Sample relapse patterns for tropical and temperate strains of P. vivax. A relapse is assumed to be 
undetected if it occurs within 14 days of a detected relapse. Both tropical and temperate phenotypes exhibit dose 
dependency, with a larger number of hypnozoites giving rise to a greater number of relapses and shorter times  
to first relapse. For larger numbers of hypnozoites (N = 50), periodicity in detected relapses is observed. The 
appearance of this periodicity is due to the undetected relapses.
DOI: 10.7554/eLife.04692.005
The following figure supplement is available for figure 1:
Figure supplement 1. Expected time between consecutive relapses. 
DOI: 10.7554/eLife.04692.006
obtainable via survival analysis of patient data (Lover and Coker, 2013; Battle et al., 2014) (Figure 3C,D). 
The expected number of relapsing hypnozoites per individual is expected to follow an approximately 
exponential distribution (Figure 3E,F) in agreement with empirical observations (Horing, 1947; 
White, 2011).
Dynamics and steady states of P. vivax transmission
Figure 4A shows the predicted steady states (the equilibrium blood-stage prevalence in the absence 
of seasonally varying transmission) as a function of entomological inoculation rate (EIR). EIR is a 
measurement of the number of infectious bites per person per year. The proportion of people 
infected with hypnozoites is predicted to be higher than the proportion infected with P. vivax 
blood-stage parasites. For a given EIR, P. vivax blood-stage prevalence is predicted to be higher 
than P. falciparum prevalence as a single mosquito bite can give rise to multiple blood-stage infec-
tions. However this does not account for the longer duration of P. falciparum infections as a con-
sequence of antigenic switching (Molineaux et al., 2001), and the important role of heterogeneity 
in exposure (Smith et al., 2005). With the exception of the P. vivax hypnozoite rate, these quanti-
ties can be measured in epidemiological field studies (Smith et al., 2005; Kelly-Hope and 
McKenzie, 2009).
Figure 4B shows how the median number of hypnozoites increases with increasing P. vivax trans-
mission. Figure 4C shows the distribution in the number of hypnozoites when PvPR = 50%. The 
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Figure 3. Predicted relapse infections following primary P. vivax infection. (A and B) Duration of hypnozoite carriage (orange) and expected number of 
hypnozoites in the liver (dashed). For the temperate strain, the dashed blue line shows the number of hypnozoites in the relapsing phase. (C and D) 
Survival time until nth relapsing hypnozoite. The red curve is equivalent to the Kaplan–Meier curve for time to first blood-stage infection that would be 
observed in the absence of new infections from mosquito bites. Only the curves for the first five relapses are shown. (E and F) Proportion of individuals 
with at least n relapsing hypnozoites following primary infection.
DOI: 10.7554/eLife.04692.007
number of hypnozoites per individual is predicted to be over-dispersed following a negative binomial 
distribution. Thus some individuals will harbour a large number of hypnozoites while some will have 
none. This phenomenon will be further amplified if there is heterogeneity in exposure where some 
individuals receive a large number of mosquito bites.
Control of P. vivax
The impact of malaria control interventions will depend on how effectively the parasite is 
targeted in each of the reservoirs in the mosquito, the blood and the liver. Figure 5 shows the 
qualitative effects of malaria control on the transmission dynamics of P. falciparum and P. vivax. 
Vector control with insecticide treated nets (ITNs) or indoor residual spraying (IRS) is assumed 
to increase mosquito mortality. The introduction of vector control is expected to cause a 
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Figure 4. Within-host model for tropical relapses embedded in a P. vivax transmission model. (A) The statics 
(estimated equilibrium prevalence) of P. vivax and P. falciparum transmission for different values of the entomologi-
cal inoculation rate (EIR). EIR was varied by changing the number of mosquitoes per person m. (B) The number of 
hypnozoites per person is expected to increase with transmission intensity. The black line denotes the median 
number of hypnozoites, and the shaded areas denote the 50% and 95% ranges. (C) The distribution of the 
hypnozoite reservoir when PvPR = 50%. The grey bar represents individuals with zero hypnozoites.
DOI: 10.7554/eLife.04692.008
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Figure 5. Timelines for malaria control. (A) The introduction of vector control with ITNs or IRS (assumed to increase 
mosquito mortality by 30%) is predicted to cause substantial reductions in both PvPR and PfPR. (B) Simulated effect 
of expanding first-line treatment with blood-stage anti-malarial drugs (e.g., chloroquine or ACTs) so that 20% and 
40% of new blood-stage infections are treated. (C) Simulated effect of first-line treatment with a combined regimen 
of blood-stage anti-malarials and primaquine to remove liver-stage hypnozoites.
DOI: 10.7554/eLife.04692.009
Figure 5. Continued on next page
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rapid decline in P. falciparum parasite rate (PfPR), and a smaller and slower decline in P. vivax  
(Figure 5A).
Figure 5B shows the effect of targeting the parasite reservoir in the blood by providing first-line 
treatment for new blood-stage infections with anti-malarial drugs such as chloroquine or artemisinin 
combination therapies (ACTs). See details of how treatment was implemented in the model are pro-
vided in Figure 5—figure supplement 1,2. Increasing treatment coverage leads to reductions in 
blood-stage prevalence of both P. falciparum and P. vivax. Notably the reduction in the P. vivax hypno-
zoite rate is slow as the hypnozoite reservoir is not directly targeted.
The hypnozoite reservoir can be directly targeted using a drug such as primaquine that can elimi-
nate hypnozoites from the liver (Wells et al., 2010). The inclusion of primaquine in first-line treatment 
regimens is predicted to cause substantial reductions in both the P. vivax parasite rate and hypnozoite 
rate (Figure 5C), as individuals being treated for blood-stage P. vivax infections will also have their 
hypnozoites removed. A consequence of this strategy is that the hypnozoite reservoir can be targeted 
efficiently, as individuals with the most hypnozoites are most likely to relapse and potentially be 
detected by health systems. Figure 6 shows how the inclusion of primaquine in first-line treatment 
regimens preferentially targets the most intense infections, with the greatest reductions observed in 
individuals with the most hypnozoites.
Discussion
Relapse infections arising from the activation of hypnozoites in the human liver have important conse-
quences for the transmission dynamics of P. vivax. Hypnozoites in the liver constitute a third malaria 
parasite reservoir, in addition to the reservoirs in the blood circulation and mosquito also present for 
P. falciparum. Relapses can be incorporated into Ross-Macdonald models of malaria transmission 
through the addition of a state to represent the hypnozoite reservoir (Roy et al., 2013), or as demon-
strated here, through consideration of the number of hypnozoites in the liver. This allows the inten-
sity of hypnozoite infection to be estimated which is crucial for understanding patterns of relapse 
infections (White, 2011) and evaluating the effect of interventions such as primaquine treatment 
that directly target the hypnozoite reservoir. Hypnozoites are assumed to be subjected to two pro-
cesses: activation at constant rate α, and death at constant rate µ. By considering infection with 
batches of hypnozoites, these simple processes can explain many of the complex patterns observed 
in P. vivax relapses (see Box 1).
A key assumption in the proposed model is the constant activation of hypnozoites. This implies that 
relapses can occur immediately after primary P. vivax infection, in contrast to suggestions that the first 
relapse does not occur until 2–3 weeks later. The best evidence on early relapses comes from treat-
ment efficacy studies where patients treated for P. vivax are followed for recurrent infection for 42 days 
(Douglas et al., 2010). Except in cases with documented chloroquine resistance (Price et al., 2014), 
recurrent infections are rarely observed prior to day 14, however the inclusion of long-lasting anti-
malarials in treatment regimens provides prophylaxis during this period making detection of parasites 
unlikely. In a recent study of the slowly eliminated drug dihydroartemisinin-piperaquine (DP) Tarning 
et al. (2014) tested a model where relapses occur in bursts every 3 weeks, but it arguably provided no 
better fit to the data than a model of constant hypnozoite activation. Testing the hypothesis of con-
stant activation would require follow up of patients treated with rapidly eliminated artemisinin mono-
therapy, a challenging proposition given the concerns over artemisinin resistant P. falciparum (Ashley 
et al., 2014).
Although the model captures the key drivers of the dynamics of P. vivax transmission, it is a simpli-
fied representation subject to a number of limiting assumptions. The potential role of triggers of 
The following figure supplements are available for figure 5:
Figure supplement 1. Transmission model incorporating treatment of new infections with blood-stage 
anti-malarials. 
DOI: 10.7554/eLife.04692.010
Figure supplement 2. Transmission model incorporating treatment of new infections with blood-stage anti- 
malarials and primaquine. 
DOI: 10.7554/eLife.04692.011
Figure 5. Continued
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hypnozoite activation such as febrile illness (Shanks 
and White, 2013) are not accounted for. There is 
no heterogeneity or seasonality in transmission, 
and no age structure. Incorporation of the acqui-
sition of natural immunity into the model will be 
particularly important for settings with high trans-
mission intensity where immunity has a role in 
regulating blood-stage infections (Mueller et al., 
2013). It is assumed that all individuals infected 
with blood-stage parasites are capable of trans-
mitting to mosquitoes. Similar to the corre-
sponding P. falciparum models, incorporation of 
these factors would change the quantitative pre-
dictions of the model, but not its qualitative 
behaviour.
P. falciparum and P. vivax parasite prevalence 
(PfPR and PvPR) are the most widely reported 
and best validated metrics of malaria transmis-
sion from epidemiological studies (Gething et al., 
2011a; Gething et al., 2012) providing measure-
ments of the proportion of individuals with detect-
able blood-stage parasites. In settings with similar 
levels of P. vivax and P. falciparum transmission, 
the model predicts PvPR to be greater than PfPR 
due to the additional blood-stage infections aris-
ing from relapses. However, this does not agree with empirical observations which find PfPR to be 
similar to or greater than PvPR (Snounou and White, 2004; Mueller et al., 2009b). This is most likely 
explained by the rapid acquisition of immunity to P. vivax (Koepfli et al., 2013; Mueller et al., 2013) 
the low detectability of P. vivax blood-stage infections (Harris et al., 2010), and the longer durations 
of P. falciparum blood-stage infection (Molineaux et al., 2001) not captured in the model. Furthermore, 
the additional P. vivax parasite reservoir in the liver means that PfPR and PvPR are not directly compa-
rable metrics. Thus if a parasitological survey indicates similar parasite prevalence, a greater con-
trol effort will be required to reduce P. vivax transmission than to reduce P. falciparum transmission 
because of the additional infections emerging from the hypnozoite reservoir. The model described 
here allows the proportion of individuals harbouring hypnozoites to be estimated given metrics such 
as PvPR. The number of hypnozoites per person is predicted to be over-dispersed with some indi-
viduals with intensely infected livers and most carrying few or no hypnozoites (Figure 4C). Estimates 
of the prevalence and intensity of hypnozoite infection will be dependent on both the uncertainty in 
the measurable data and the model assumptions.
Vector control with ITNs or IRS, and treatment with effective anti-malarial drugs are the corner-
stones of malaria control efforts targeting the parasite in the vector and the human host, however 
they are predicted to have different effects on P. vivax and P. falciparum transmission. Vector control 
interventions that increase mosquito mortality are expected to cause greater reductions in PfPR 
than PvPR (Figure 5A), as higher levels of P. vivax transmission can be maintained with fewer mos-
quito bites. This has been observed in both Thailand (Sattabongkot et al., 2004) and Brazil (Coura 
et al., 2006) where increased vector control has caused greater reductions in P. falciparum than 
P. vivax.
First-line treatment of new blood-stage infections with anti-malarial drugs such as chloroquine or 
ACTs is predicted to cause moderate reductions in blood-stage prevalence of both P. falciparum and 
P. vivax (Figure 5B). The addition of primaquine to first-line treatment regimens is expected to cause 
large reductions in P. vivax blood-stage prevalence, as individuals with the most intense hypnozoite 
infections are more likely to relapse and be targeted for treatment and hence have their hypnozoites 
eliminated. The potential to simultaneously target parasite reservoirs in the blood and liver may turn 
the cause of P. vivax parasites' robust transmission into its Achilles' heel.
In P. vivax and P. falciparum co-endemic regions, heterogeneity in exposure to mosquito bites 
may cause associations between P. falciparum fevers and the risk of future P. vivax relapses 
Figure 6. Targeting the hypnozoite reservoir. Proportion 
of the population infected with 1–2, 3–9  
or 10+ hypnozoites following the introduction of a 
first-line treatment regimen with blood-stage anti-
malarial drugs and primaquine. Individuals with large 
numbers of hypnozoites are more likely to experience 
new blood-stage infections and hence become 
targeted for treatment and have their hypnozoites 
removed. This results in a selective targeting of the 
most intensely infected individuals.
DOI: 10.7554/eLife.04692.012
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Box 1. Properties of predicted P. vivax relapse patterns 
Nicholas White (White, 2011) has argued that a theory seeking to explain the remarkable biology 
of P. vivax relapses must accommodate eight phenomena. The within-host relapse model proposed 
here accounts for six of these, and can be extended to accommodate the other two.
 
•	 Relapses show remarkable periodicity. The assumption of constant hypnozoite activation and 
death does not allow for periodic relapses. However if we assume some relapses are undetected 
due to prophylaxis following treatment or the presence of existing blood-stage parasites, an 
apparent periodicity in detected relapses is predicted (Figure 2).
•	 For tropical strains of P. vivax the highest incidence of relapses is predicted to be immediately 
after primary infection (Figure 1), thus the first relapses will be detected after the prophylactic 
effects of treatment have waned.
•	 Not all P. vivax infections are followed by relapses. Individuals will avoid relapses if the number of 
initial hypnozoites is zero, or if hypnozoites die before relapsing (Figure 3D).
•	 Multiple relapses are common. The within-host model predicts an approximately exponential 
distribution in the numbers of relapsing hypnozoites per person (Figure 3E,F). Dose-dependency 
in the number of relapses is predicted, with greater numbers of hypnozoites giving rise to greater 
numbers of relapses.
•	 The time to first relapse for temperate strains is predicted to follow a gamma distribution (approx-
imately Normal).
•	 After the first relapse of a temperate strain, the intervals between consecutive relapses are pre-
dicted to be similar to those observed in tropical strains (Figure 2).
 
The model described here does not account for the varying genotypes arising from single or mul-
tiple mosquito bites, although it can be extended to account for the diversity of genotypes in the 
hypnozoite reservoir (Koepfli et al., 2011, 2013). The model represents a baseline scenario with 
constant hypnozoite activation and death in the absence of external triggers. The role of triggers 
such as fever can be tested for in detail with data on the timing and peak temperatures of episodes 
of febrile illness.
DOI: 10.7554/eLife.04692.013
(Douglas et al., 2011). Thus the inclusion of primaquine in first-line treatment for P. falciparum may 
also reduce P. vivax transmission. In addition to inclusion in first-line treatment regimens, primaquine 
can also be administered as part of mass drug administration (MDA) programmes. In treatment-
reinfection studies of Papua New Guinean children (Betuela et al., 2012; Robinson et al., unpub-
lished), mass administration of drugs such as chloroquine or artemether-lumefantrine successfully 
cleared P. vivax blood-stage infections but rapid recurrence of infection was observed during fol-
low-up—most likely due to relapses. The addition of primaquine to the treatment regimen caused 
large reductions in the rate of recurrent infections.
Although primaquine treatment clears the hypnozoite reservoir, it requires a difficult 14 day treat-
ment regimen, and is not without risk due to vulnerability to haemolytic toxicity among glucose-
6-phosphate dehydrogenase (G6PD) deficient patients (Howes et al., 2013). Individuals should thus 
be tested for G6PD deficiency (Kim et al., 2011) before the administration of primaquine. A prima-
quine analogue, tafenoquine, is currently undergoing phase three trials and is likely to be licensed 
for use by 2017 (Llanos-Cuentas et al., 2014). Tafenoquine requires a single dose alongside a 3 day 
chloroquine regimen, but is subject to the same risks in G6PD deficient patients. A quantitative model 
of P. vivax transmission will allow for the benefits of primaquine treatment to be weighed against the 
risks of G6PD deficiency and the costs of G6PD testing.
Mathematical models of malaria transmission that account for P. vivax relapses can provide valu-
able insights into the impact of malaria control interventions on the parasite's reservoirs in the 
vector, the blood and the liver. In the absence of effective diagnostics for detecting liver-stage para-
sites (malERA Consultative Group on Diagnoses and Diagnostics, 2011), models will play a crucial 
role in estimating and predicting the effectiveness of interventions that target the hypnozoite reser-
voir, either indirectly via vector control and blood-stage anti-malarials or directly via primaquine 
treatment.
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Figure 7. Within-host model schematic of relapsing hypnozoites in the liver. Hypnozoites from tropical strains of  
P. vivax will progress to the relapsing phase where they are subject to two processes: death and activation leading 
to relapse. Hypnozoites from temperate strains will begin in a temperate long-latency phase where they must wait 
before progressing to the relapsing phase.
DOI: 10.7554/eLife.04692.014
The following figure supplement is available for figure 7:
Figure supplement 1. Detailed model schematic of the within-host relapse model. 
DOI: 10.7554/eLife.04692.015
Materials and methods
Within-host model for tropical relapses
Following infection with a tropical strain of P. vivax, the population dynamics of hypnozoites in the 
liver can be described by a within-host model where each hypnozoite is subject to two processes: 
(i) activation leading to relapse infection; and (ii) death, either of the hypnozoite itself or the host hep-
atocyte (Malato et al., 2011). Constant activation (α) and death (µ) rates are assumed implying hypno-
zoite residence time in the liver is exponentially distributed. The long latency of temperate strains 
before first relapse can be accounted for by assuming a period of dormancy during which hypno-
zoites must wait before they can activate. A schematic representation of the within-host model is 
presented in Figure 7.
The tropical relapse model is assumed to begin with an initial population of N hypnozoites, each of 
which can either activate at rate α, or die at rate µ, independently of each other. The number of hyp-
nozoites in the liver will decay exponentially with an expected Ne−(µ+α)t hypnozoites at time t. Let ( )N
i
H t  
denote the probability that i of N hypnozoites remain in the liver after time t. The hypnozoite popula-
tion dynamics can be described by the following set of equations:
( )
( ) ( ) +1
= – +
= – + + + ( +1) ,   = 0... – 1
N
NN
N
N
N Ni
i i
dH
NH
dt
dH
iH i H i N
dt
μ α
μ α μ α
 
(1)
Equation 1 can be solved analytically to give:
( ) ( ) –– ( + ) ( + )= – 1 N iN N t ti NH t e e
i
     
μ α μ α
 
(2)
Define ( )NjP t  to be the probability that j relapses have occurred by time t. This can be calculated as 
follows: if i hypnozoites remain in the liver, then N − i have either activated or died. The probability of 
each hypnozoite activating is 
+
α
μ α . The probability that j of N − i hypnozoites have activated can 
thus be calculated from a binomial distribution. Summing over the allowable number of hypnozoites 
(at least j hypnozoites must have activated or died for j relapses to be observed) gives:
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( )
( ) ( )
– ––
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––
–( + )
( + )
–
= ( )
+ +
+ 1
= 1– 1+
–1+
j N i jN j
N N
j i
i
N jj N j
Nt
N t
N i
P t H t
j
N
e
j e
                     
             
∑
μ α
μ α
α μ
μ α μ α
α μ μ α
μμ α  
(3)
Equations 1–3 describe the population dynamics of hypnozoites in a single individual with N hyp-
nozoites in the absence of exposure to new infections. In a population of individuals, we would expect 
substantial variation in the numbers of hypnozoites due to heterogeneity in exposure and the variation 
in sporozoite inoculum from each infectious mosquito bite (Beier et al., 1991; Medica and Sinnis, 
2005; White et al., 2013). Based on evidence that the number of sporozoites injected with a mosquito 
bite approximately follows a geometric distribution (Beier et al., 1991), we assume that the number 
of hypnozoites following a primary infection is also geometrically distributed. If the mean number of 
hypnozoites is N, then the probability of k hypnozoites is 1
+1 +1
k
N
N N
    
. Assuming a geometrically dis-
tributed number of hypnozoites, the three quantities describing the epidemiology of relapses can be 
estimated in terms of the within-host parameters. The expected number of relapsing hypnozoites is:
=0
probability of k probability of each
initial hypnozoites hypnozoite relapsing
1
=       =
+1 +1 + +
k
k
N
h k N
N N
    ∑
 
α α
α μ μ α
∞
 
(4)
The mean duration of hypnozoite carriage is:
( )
=0 =1
probability of duration of 
initial hypnozoites  hypnozoites
log +11 1 1 1
= =
+1 +1 + +
k k
k i
k
k
NN
N N i
    ∑ ∑
 
γ μ α μ α
∞
 
(5)
The expected time to first relapse is:
–
probability of k probability of hypnozoite i being first to relapse
initial hypnozoites
1 1
= 1–
+ + ++1
k i kk
N
f N N
                                          
μ α μ
μ α μ α μ α
–
=1 =1 =0
time to relapse
1 1
– +
k k i
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∑ ∑ ∑

 
μ α
∞
 
(6)
The within-host relapse model describes a baseline scenario in the absence of potential external 
triggers for relapse such as fever (Shanks and White, 2013). Underlying assumptions of this model 
are: (i) each hypnozoite acts independently of other hypnozoites, for example, hypnozoites will not 
activate in batches due to mechanisms such as quorum sensing; and, (ii) hypnozoite death occurs at a 
constant rate, due to either death of the hypnozoite within the hepatocyte or death of the hepatocyte 
itself (Malato et al., 2011). The activation of a hypnozoite may not directly correspond to a detected 
relapse. For example, an infection arising from two hypnozoites activating within a day of each other 
is likely to be classified as a single relapse.
Within-host model for temperate relapses
The within-host model can be extended to account for temperate strains of P. vivax. We assume that 
before a hypnozoite is capable of activating, it must undergo a long-latency phase of duration d. 
During this period hypnozoites are subject to death at rate µ. In particular, we assume that the time 
spent in the temperate long-latency phase can be described by a gamma distribution with mean d and 
variance d2/M. This gamma distribution can be simulated by M successive compartments with expo-
nential waiting times 1/δ = d/M. Increasing the number of compartments M reduces the variance in 
the duration of the dormancy period (Wearing et al., 2005). Following a primary infection where N 
hypnozoites of a temperate phenotype develop in the liver, we define 
,
N
i jL  as the probability that i of N 
hypnozoites are waiting in long-latency compartment number j, then the number of dormant and po-
tentially active hypnozoites can be described by the following system of differential equations.
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(7)
The equations are presented schematically in Figure 7—figure supplement 1. Equation 7 cannot 
be solved analytically and must be computed numerically to calculate ( )N
i
H t  and ( )
,
N
i jL t . A greater 
deal of uncertainty surrounds the biological processes accounting for the initial long-latency phase 
observed in temperate strains of P. vivax. In the model implemented here, it is assumed that all 
hypnozoites in an infection must undergo some waiting period before any of them can activate, 
and that during the long-latency phase hypnozoites are at risk of death due to natural hepatocyte 
death.
P. vivax transmission model
We next embedded the within-host model for tropical relapses in a model for the transmission of 
P. vivax between humans and mosquitoes (Figure 8). The transmission dynamics are driven by two 
processes: (i) transmission of parasites through mosquito bites; and (ii) relapsing of liver-stage hyp-
nozoites to cause new blood-stage infections. As per the standard Ross-Macdonald theory, the 
force of blood-stage infections in humans can be calculated as the product of the number of mos-
quitoes per human m, the rate at which each mosquito bites a human host a, the probability of 
transmission from mosquito to human following an infectious bite b, and the proportion of mosqui-
toes that are infectious IM, to give λ = mabIM. Parameter values are provided in Table 1. The force of 
infection on mosquitoes can be calculated in a similar manner. We assume that people can be sus-
ceptible (Si) or infected with blood-stage parasites (Ii), where i denotes the number of hypnozoites 
in the liver.
The increase in hypnozoites in the liver is determined by the force of infection λ and the number of 
hypnozoites per infection N, and the decrease is due to hypnozoite activation α and death µ. The 
model depicted in Figure 8 can be described by the following set of equations:
( )
( )
( )
+1
=0
+1 +1
–
=0
–
=0
= – – ( + )S + ( +1) +     = 0...
= – + + – ( + )
+ ( +1)( + ) + ( +1) –      = 0...
= – – –
= – –
i
i i i i i
i
i
i j i j j i
j
i i i i
gnM
i M M
i
gnM
i M M
i
dS
S i i S I i
dt
dI
I S I i I
dt
i I i S I i
dS
g ac I e I gS
dt
dI
ac I e I gI
dt
     
     
∑
∑
∑
λ μ α μ ρ
λ λ μ α
μ α α ρ
→
∞
∞
∞
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(8)
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where 
–
1
=
+1 +1
i j
j i
N
N N
    λ λ→ . In the absence of 
super-infection, the recovery from blood-stage 
infection is =
i
rρ . Accounting for super-infections 
(Dietz and Molineaux, 1973; Smith et al., 2012) 
gives 
+
+
=
–1
i
r
i
i
e
λ α
λ αρ .
Model parameterisation
The within-host model for tropical relapses was 
fitted in a Bayesian framework to data on time 
to first relapse infection from three ecological 
zones with tropical strains of P. vivax: South 
America, South East Asia and Melanesia (see 
Source data 1). The data are described in detail 
by Battle et al. (2014). Individual-level data on 
time to first recurrence was collated from indi-
viduals exposed to P. vivax infection (either via 
natural exposure or artificial challenge) and 
mostly followed up in the absence of exposure 
to new infections (Battle et al., 2014). The like-
lihood of the tropical relapse model can be eval-
uated by applying the model to the data on 
time to first relapse infection. The first detected 
relapse will occur after clearance of parasites 
from the primary infection and after the period 
of prophylactic protection from anti-malarial 
drugs. Define QN(t) to be the probability that 
at least 1 of N hypnozoites has relapsed by 
time t.
–( + )
0
+
( ) =1– ( ) =1–
+
N
t
N N e
Q t P t
     
μ αμ α
μ α  
(9)
Accounting for a geometrically distributed 
number of hypnozoites gives:
( ) ( )( )
=0
1
=
+1 +1
k
G N k
k
N
Q t Q t
N N
    ∑
∞
 
(10)
where G(N) denotes a geometric distribution.
An individual j followed up after a primary P. vivax infection will either relapse (Ij = 1) or avoid infec-
tion (Ij = 0). Denote τj to be the time of detection of infection, or if uninfected, the time until the end 
of follow up. The likelihood of the parameters θ = {N, α, µ} given the data Dj = {Ij, τj} is:
( ) ( )
( )
1–
( )
=
= 1– ( )
j
j
j
I
G N
IG N
j j
t
dQ
L D Q
dt
       τ
θ τ
 
(11)
The log-likelihood (LL) for all j individuals is:
( ) ( )
( )
( )
=
= log + 1– log 1– ( )
j
G N
G N
j j j
j t
dQ
LL I I Q
dt
                
∑
τ
τ
 
(12)
Data on time to first relapse were not sufficiently informative to estimate the three parameters simulta-
neously and hence prior distributions were assumed. N was assumed to have an informative gamma prior 
Figure 8. Transmission model schematic. Within-host 
model for tropical relapses embedded in a transmission 
model. Si denotes the proportion of humans suscepti-
ble to blood-stage infection with i hypnozoites. Ii 
denotes the proportion of humans with blood-stage 
infections carrying i hypnozoites. Individuals in all 
compartments are exposed to primary infections at rate 
λ, following which they will move down the flow 
diagram to a compartment representing blood-stage 
infection and carrying a greater number of hypnozoites.
DOI: 10.7554/eLife.04692.016
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distribution with median 10 (95% credible interval (CrI): 1, 28) (Beier et al., 1991). µ was assumed to have 
an informative gamma prior distribution with median 1/200 (95% CrI: 1/309, 1/140) day−1 (Malato et al., 
2011). α was assumed to have an uninformative uniform prior distribution U(0,1). The likelihood in equation 
(Ishikawa et al., 2003) was sampled using a Metropolis–Hastings Markov Chain Monte Carlo (MCMC) 
algorithm and the posterior parameter distributions estimated (Figure 1—figure supplement 1). The pos-
terior median parameter estimates and 95% credible intervals are presented in Supplementary file 1.
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